Benitec Biopharma (BNTC) Net Income towards Common Stockholders (2019 - 2025)

Benitec Biopharma has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$11.8 million in Q4 2025.

• Quarterly Net Income towards Common Stockholders fell 23.92% year-over-year to -$11.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$44.1 million (down 86.82% YoY) and the FY2025 annual result came in at -$37.9 million, down 69.5% from the prior year.
• Net Income towards Common Stockholders fell to -$11.8 million in Q4 2025 per BNTC's latest filing, from -$9.0 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$3.6 million in Q1 2022 and troughed at -$16.4 million in Q2 2023.
• A 5-year average of -$7.1 million and a median of -$5.6 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2021 and 2025: Net Income towards Common Stockholders soared 74.98% in 2021, then slumped 238.89% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$5.0 million in 2021, then fell by 27.07% to -$6.3 million in 2022, then decreased by 7.27% to -$6.8 million in 2023, then slumped by 40.51% to -$9.6 million in 2024, then dropped by 23.92% to -$11.8 million in 2025.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$11.8 million, -$9.0 million, and -$8.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.